TRANS-
FORMATION
Unlocked
At Elixir we believe that only by harnessing the power of transformation can there be real-world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.
We are a company developing disruptive platforms to treat coronary and peripheral artery disease.
TRANSFORMATION.
TRANS-
FORMA-
TION.
Unlocked.
At Elixir we believe that only by harnessing the power of transformation can there be real world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.
We are a company developing disruptive platforms to treat coronary and peripheral artery disease.
CVDs are leading cause of death
244.1 million
About 6 million
patients undergo PCI (Percutaneous Coronary Intervention) every year
$407.3 billion
in direct and indirect cost in the United States3
805,000 annual heart attacks in US
20% of patients experience an adverse event
within 5 years after PCI procedure4
Our technologies
DynamX bioadaptor is a coronary implant that is designed to not only restore blood flow, but to also unlock and uncage the vessel, allowing the artery to return to its natural physiology, motion and function while DynamX continues to provide dynamic support.
LITHIX™ HERTZ CONTACT LITHOTRIPSY (HC-IVL) CATHETER
The LithiX HC-IVL Catheter is designed to use Hertz contact stress to harness the power of physics and mechanics to fracture calcium. It is designed with deliverability, safety and simplicity of use in mind.
SITE-SPECIFIC ANTITHROMBOTIC THERAPY
We developed the world’s first site-specific antithrombotic therapy using two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor, sirolimus. The technology is designed to address challenges associated with percutaneous coronary intervention (PCI), including management of thrombotic and bleeding risk.
References
- https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
- https://professional.heart.org/
-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-GIobal-Burden-of-Disease.pdf - https://www.ahajournals.org/doi/epub/
10.1161/CIR.0000000000001123 - https://www.ahajournals.org/doi/full/
10.1161/CIRCINTERVENTIONS.114.002230
- https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
- https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-GIobal-Burden-of-Disease.pdf
- https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001123
- https://www.ahajournals.org/doi/full/10.1161/CIRCINTERVENTIONS.114.002230
PMN 2137 Rev A